SCHEMBL2010124

SCHEMBL2010124

CCCCS(=O)(=O)[N]CC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 2/20 0.41
NPC1 O15118 1/20 0.41
S1PR2 O95136 1/20 0.41
S1PR4 O95977 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 1/20 0.41
XBP1 P17861 1/20 0.41
S1PR1 P21453 1/20 0.41
MAPK1 P28482 1/20 0.41
AGTR1 P30556 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
FAAH O00519 2/20 0.37
CA2 P00918 6/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7309994 0.92 FAAH (0.46) ALDH1A1MAPTLMNANPC1S1PR2
SCHEMBL7311233 0.90 FAAH (0.50) FAAHCA2TSHR
SCHEMBL2008849 0.83
SCHEMBL7685785 0.82 ALDH1A1 (0.39) ALDH1A1MAPTLMNANPC1S1PR2
SCHEMBL7695237 0.82 ALDH1A1 (0.39) ALDH1A1MAPTLMNANPC1S1PR2
SCHEMBL7687551 0.80 FAAH (0.39) ALDH1A1MAPTLMNANPC1S1PR2
SCHEMBL7688964 0.78 FAAH (0.43) ALDH1A1MAPTLMNANPC1S1PR2
SCHEMBL239450 0.78 ALDH1A1 (0.44) ALDH1A1MAPTLMNANPC1S1PR2
SCHEMBL1513027 0.76
SCHEMBL7694637 0.75 FAAH (0.44) ALDH1A1MAPTLMNANPC1S1PR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359350-B2 Ring-fused compound SATO PHARMACEUTICAL CO., LTD. (JP) 2016-06-07 US disclosed
US-20150203490-A1 RING-FUSED COMPOUND SATO PHARMACEUTICAL CO., LTD. (JP) 2015-07-23 US disclosed
US-8987473-B2 Ring-fused compound SATO PHARMACEUTICAL CO., LTD. (JP) 2015-03-24 US disclosed
EP-1717230-B1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE MSD KK (JP) 2014-08-06 EP disclosed
US-20140005221-A1 RING-FUSED COMPOUND SATO PHARMACEUTICAL CO., LTD. (JP) 2014-01-02 US disclosed
EP-2669270-A1 RING-FUSED COMPOUND Sato Pharmaceutical Co., Ltd. (JP) 2013-12-04 EP disclosed
EP-1642898-B1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE MSD KK (JP) 2013-03-27 EP disclosed
US-8268842-B2 Fused ring 4-oxopyrimidine derivative MSD K.K. (JP) 2012-09-18 US disclosed
US-8163770-B2 Benzoxathiin derivative MSD. K. K. (JP) 2012-04-24 US disclosed
US-8044070-B2 Heteroaryloxy nitrogenous saturated heterocyclic derivative MSD K.K. (JP) 2011-10-25 US disclosed
WO-1997009324-A1 2-CYCLOHEXANE-1,3-DIONE BENZOYL DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 1997-03-13 WO disclosed
WO-1997009327-A1 PYRAZOL-4-YL-BENZOYL DERIVATIVES AND THEIR USE AS HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1997-03-13 WO disclosed
US-5602127-A ADMINISTERING TO TREAT HYPERTENSION KARL THOMAE GMBH (DE) 1997-02-11 US disclosed
US-5594003-A HYPOTENSIVE AGENTS DR. KARL THOMAE GMBH (DE) 1997-01-14 US disclosed
US-5591762-A HYPOTENSIVE AGENTS DR. KARL THOMAE GMBH (DE) 1997-01-07 US disclosed
WO-1996037471-A1 N-AMINOPYRIDONE DERIVATIVES AND THEIR USE AS HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1996-11-28 WO disclosed
WO-1996026192-A1 ISOXAZOLYL-BENZOYL DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 1996-08-29 WO disclosed
WO-1996026193-A1 PHENYL DIKETONE DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 1996-08-29 WO disclosed
WO-1996026200-A1 HERBICIDAL BENZOYL DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 1996-08-29 WO disclosed
EP-0502314-A1 Benzimidazol, medicaments containing them and process for their preparation Dr. Karl Thomae GmbH (DE) 1992-09-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203490-A1 RING-FUSED COMPOUND URB2, RCOR1, RCC2 ALDH1A1 487/4885MAPT 966/4885LMNA 2526/4885
US-20140005221-A1 RING-FUSED COMPOUND URB2, RCOR1, RCC2 ALDH1A1 487/4885MAPT 966/4885LMNA 2526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.